Celldex Therapeutics
Logotype for Celldex Therapeutics Inc

Celldex Therapeutics (CLDX) investor relations material

Celldex Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Celldex Therapeutics Inc
3rd Annual Guggenheim Healthcare Innovation Conference summary9 Nov, 2026

Barzolvolimab phase III results

  • Phase III CSU results showed complete response in a majority of patients, prospective angioedema clearing at 12 weeks, and similar responses in omalizumab-refractory patients.

  • One regimen requires seven dosing days per year; HCPs highlighted rapid, durable responses that deepen over time, severe disease with angioedema, and biologic-refractory patients as key differentiators.

  • Phase II follow-up showed 41% of patients remained in complete response seven months after their last dose; phase III off-therapy durability data will follow treatment through 52 weeks and subsequent follow-up.

  • The overall safety profile was described as favorable; common KIT-mediated adverse events were mostly mild to moderate and expected to reverse, while serious and grade 3/4 event rates matched placebo.

  • Two phase III cases were adjudicated as probable anaphylaxis, both after the first barzolvolimab dose; a separate adjudicated anaphylaxis case occurred on placebo.

Regulatory and data milestones

  • BLA submission is guided for 2027, using the full 52-week data; the goal is to bring the therapy to patients as quickly as possible.

  • At AAAAI in February 2027, the planned presentation will cover 24-week efficacy, including primary and key secondary endpoints, 12- and 24-week results, and time course.

  • Additional presentations on secondary and exploratory endpoints are planned in the coming months; phase III off-therapy follow-up will come after the 52-week treatment period.

  • CIndU phase III trials are enrolling; further guidance is expected in the next few months. Atopic dermatitis data are expected by year-end, from a moderately severe population that allows prior therapies, including biologics.

Market and commercialization

  • In the U.S., an estimated 30% of CSU prevalence is diagnosed, and fewer than 20% of diagnosed patients clinically eligible for advanced therapy receive one.

  • Barzolvolimab is positioned for first-line patients with severe disease or angioedema, estimated at at least 25% of first-line patients, and as a second-line option for patients with ongoing symptoms.

  • Other therapies have complete response rates of 30%–38%; one-year real-world attrition for patients starting omalizumab or dupilumab is 50%, supporting a substantial second-line opportunity.

  • Preliminary payer discussions support a premium, value-based pricing strategy; commercial preparations include expanding the MSL team and building market analytics, brand, and payer teams.

  • Payer exchange under PIE is anticipated in H1 2027; infrastructure development is described as disciplined, data-based, milestone-driven, and focused on high-value prescriber accounts.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Celldex Therapeutics earnings date

Logotype for Celldex Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026
Celldex Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Celldex Therapeutics earnings date

Logotype for Celldex Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutic monoclonal and bispecific antibodies. These antibodies are designed to treat a range of serious conditions, including inflammatory, allergic, and autoimmune diseases. The company's lead program focuses on developing barzolvolimab, a monoclonal antibody targeting KIT, a key receptor tyrosine kinase involved in mast cell function, which is crucial in the onset and progression of various severe diseases. Celldex Therapeutics is headquartered in Hampton, New Jersey, and its shares are listed on the NASDAQ.